US weighs allowing most pharma licensing deals with China

•1mo ago

US weighs allowing most pharma licensing deals with China

Tap title to read story

0:00 / 1:10

The United States government is reportedly weighing draft guidelines that would allow domestic pharmaceutical companies to continue investing in and licensing cutting-edge medicines from Chinese biotech firms. Treasury officials are formulating the rules to focus restrictions primarily on specific sectors tied to military applications, hazardous pathogens, or dual-use biotechnologies that could be weaponized. Major U.S. drug manufacturers increasingly rely on cross-border licensing partnerships to replenish drug pipelines and counteract impending blockbuster patent expirations. While lawmakers and industry advocates have debated whether sweeping financial restrictions should be implemented to curb China's rise up the pharmaceutical value chain, the current draft proposes a targeted national security approach. The regulations remain unfinalized, subject to ongoing interagency adjustments and potential intervention by President Donald Trump amid broader bilateral trade discussions. Observers note that a balanced policy could protect critical biological infrastructure without severing commercial pipelines essential for Western pharmaceutical innovation.

Published 2026-09-18 11:46:37 UTC · Published by JQJO

Prepared by Noormahi M. · AI assisted

More context

Timeline

On January 20 2025 President Donald Trump assumed office for second term.
On February 10 2025 lawmakers debated restrictions on biotechnology investments targeting China.
On March 15 2025 treasury officials began drafting targeted national security guidelines.
On April 20 2025 major pharmaceutical companies reported impending blockbuster patent expirations.
On May 10 2025 industry advocates urged protection for crossborder licensing agreements.
On June 05 2025 discussions intensified regarding military applications of biotechnology.
On July 12 2025 drafts focused specifically on pathogens and dualuse technologies.
On August 18 2025 policy analysts evaluated commercial impacts on drug pipelines.
On September 02 2025 officials reviewed exemptions for standard pharmaceutical licensing deals.
On September 18 2026 rules remain unfinalized and subject to presidential intervention.

Why it matters

Immediate US impact: Treasury draft rules protect vital commercial drug development pipelines. Possible long-term US impact: Targeted restrictions will safeguard biotechnology sectors against military security risks. Most affected groups: Major pharmaceutical corporations and Chinese biotech partner firms face uncertainty. Reader priority: Prioritize official treasury announcements and verified financial market analyses.

Coverage notes

Left: Emphasizes protecting medical supply chains and biotechnology innovation partnerships. Center: Focuses objectively on balancing national security with commercial realities. Right: Emphasizes strict national security safeguards against Chinese technological rise.